Recurrent C. difficile infections (rCDI) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Clostridium difficile infection (CDI) is an anaerobic spore-forming bacillus that colonizes the intestinal tract in patients whose normal gut microbiota is disrupted by antibiotic therapy or any other reason. C difficile produces two major toxins—toxins A and B—that cause intestinal mucosal injury, diarrhea, and colitis. In some cases, fulminant infection leads to shock, ileus, and toxic megacolon. In high-income countries, C. difficile is the most common cause of infectious diarrhea in hospitalized patients. Between 20% and 35% of patients with C. difficile infection will fail initial antibiotic treatment, and, of these, 40–60% will have a second recurrence. Recurrence of C. difficile infection after initial treatment causes substantial morbidity and is a significant burden on health care systems. Antibiotics are the mainstay treatments for primary and recurrent CDI, with a recent trend toward vancomycin and fidaxomicin over metronidazole. Recurrent infections affect 15-35 percent of CDI patients. CDI is frequently a relapse of the same infection rather than a new strain infection. Following the first recurrence, second and subsequent recurrences are even more common.

The incidence of Clostridium difficile infection ranges from 0.8 Mn to 1 Mn in the USA and is higher among females.

 

The competitive landscape of Recurrent C. difficile infections (rCDI) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Recurrent C. difficile infections (rCDI) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Recurrent C. difficile infections (rCDI) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Recurrent C. difficile infections (rCDI) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          SER-109           Seres Therapeutics, Inc.            Phase 3

2          RBX2660          Rebiotix Inc.      Phase 3

3          CP101  Finch Research and Development LLC.  Phase 2

4          MBK-01            Mikrobiomik Healthcare Company S.L.   Phase 3

5          VE303  Vedanta Biosciences, Inc.          Phase 2

6          GS-CDA1/MDX-1388     MassBiologics   Phase 2

7          (MK-3415A-002)           Merck Sharp & Dohme LLC       Phase 3

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more